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Antidepressant use and risk of epilepsy and
seizures in people aged 20 to 64 years:
cohort study using a primary care database
Trevor Hill1, Carol Coupland1*, Richard Morriss2, Antony Arthur3, Michael Moore4 and Julia Hippisley-Cox1
Abstract
Background: Epilepsy is a serious condition which can profoundly affect an individual’s life. While there is some
evidence to suggest an association between antidepressant use and epilepsy and seizures it is conflicting and not
conclusive. Antidepressant prescribing is rising in the UK so it is important to quantify absolute risks with individual
antidepressants to enable shared decision making with patients. In this study we assess and quantify the
association between antidepressant treatment and the risk of epilepsy and seizures in a large cohort of patients
diagnosed with depression aged between 20 and 64 years.
Methods: Data on 238,963 patients with a diagnosis of depression aged 20 to 64 from 687 UK practices were
extracted from the QResearch primary care database. We used Cox’s proportional hazards to analyse the time to
the first recorded diagnosis of epilepsy/seizures, excluding patients with a prior history and estimated hazard ratios
for antidepressant exposure adjusting for potential confounding variables.
Results: In the first 5 years of follow-up, 878 (0.37 %) patients had a first diagnosis of epilepsy/seizures with the
hazard ratio (HR) significantly increased (P < 0.01) for all antidepressant drug classes and for 8 of the 11 most
commonly prescribed drugs. The highest risks (in the first 5 years) compared with no treatment were for trazodone
(HR 5.41, 95 % confidence interval (CI) 3.05 to 9.61, number needed to harm (NNH) 65), lofepramine (HR 3.09, 95 %
CI 1.73 to 5.50, NNH 138), venlafaxine (HR 2.84, 95 % CI 1.97 to 4.08, NNH 156) and combined antidepressant
treatment (HR 2.73, 95 % CI 1.52 to 4.91, NNH 166).
Conclusions: Risk of epilepsy/seizures is significantly increased for all classes of antidepressant. There is a need for
individual risk-benefit assessments in patients being considered for antidepressant treatment, especially those with
ongoing mild depression or with additional risk factors. Residual confounding and indication bias may influence our
results, so confirmation may be required from additional studies.
Keywords: Antidepressants, SSRI, TCA, Depression, Epilepsy, Seizures, Primary care database, Survival analysis
Background
In the UK, antidepressant prescribing has been rising in
recent years [1]; in 2012 more than 50 million anti-
depressant prescriptions were dispensed in England
alone [2]. There is some evidence that treatment with
antidepressants is associated with an increased risk of
epilepsy and seizures [3, 4], however few long-term stud-
ies have been carried out in the general population.
Epilepsy affects more than 500,000 people in the UK,
meaning around 1 in 100 suffer from the condition [5].
Epilepsy is not only a serious and debilitating disease,
with treatment which can be quite problematic [6], but
individuals with epilepsy are more likely to suffer from
several psychiatric disorders, including major depression
[7]. In addition there is evidence of a bidirectional asso-
ciation between depression and epilepsy/seizures [8]. In
a previous study [4, 9] of patients with depression over
the age of 65, we found that certain antidepressants were
associated with an increased risk of epilepsy/seizures.
Large scale primary care database studies provide the
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opportunity to test whether there are clinically import-
ant differences between individual antidepressants and
the risk of epilepsy/seizures. Furthermore they provide
an opportunity to calculate absolute risk that can be
considered alongside other benefits and risks of pre-
scribing antidepressants. We therefore carried out a
study to look at the risk of epilepsy/seizures in adults
aged 20 to 64 years taking antidepressants. We aimed to
assess and quantify the change in absolute risk of epi-
lepsy/seizures associated with antidepressant use, in a
population with no known predisposition to epilepsy or
seizures.
Methods
The cohort study was designed to assess and quantify
associations with antidepressant treatment for a number
of different safety outcomes including epilepsy/seizures.
Full details of the study design and methods can be
found in the published study protocol [10].
Study cohort
Patient data from 687 general practices across the UK
was extracted from the QResearch primary care database
(version 34), a large repository of anonymised health re-
cords for more than twelve million patients registered
with general practices using the Egton Medical Informa-
tion System (EMIS).
Patients were selected for the cohort if they had a first
recorded diagnosis of depression between the ages of 20
to 64, and within the study period (1/1/2000 to 31/7/
2011). To allow for at least 12 months of follow-up the
study end date was set to 1/8/2012. Identification of pa-
tients with a diagnosis of depression was achieved using
clinical Read codes that have been used in previous stud-
ies [4, 11]. Depression in the UK is largely diagnosed
and treated in primary care without the input of special-
ist assessment and there is no widespread formal screen-
ing for depression using validated tools.
The study entry date for each patient was defined as
either: the date of their first recorded diagnosis of de-
pression, or the date of their first antidepressant pre-
scription if that occurred before the diagnosis date and
within 36 months of diagnosis. To ensure only patients
with a first diagnosis of depression were included in the
cohort, eligible patients had to be diagnosed with de-
pression at least 12 months after registering with the
practice and after the date the EMIS system was
installed.
Patients with a recorded diagnosis of depression before
the study entry date and those prescribed antidepres-
sants before this date, before their date of registration
with the practice, before the age of 20 or more than
36 months before their first recorded diagnosis of de-
pression were excluded. Temporary residents, patients
with diagnoses of schizophrenia, bipolar disorder or
other types of psychosis, or those prescribed lithium or
anti-manic drugs at the study entry date were also ex-
cluded. In addition, although we have included the num-
ber of patients receiving MAOI prescriptions, and the
number with a previous history of epilepsy/seizures in
descriptive results, before proceeding with the main ana-
lyses, patients satisfying either of these criteria were
dropped from the cohort.
Follow-up continued until the earliest date of: the pa-
tient’s first recorded diagnosis of epilepsy/seizures, the
patient left the practice, death, or the end of the follow-
up period (1/8/2012). This became the patient’s study
exit date.
Outcomes
The outcome was the first recorded diagnosis of epi-
lepsy or a seizure in the patients’ primary care med-
ical record. This outcome was identified using 88
separate Read codes for epilepsy/seizures (see Additional
file 1: Table S1).
Exposure data
Data on antidepressant prescriptions during follow-up
were extracted, including the date of each prescription,
the antidepressant drug name, the dose of each tablet in
milligrams, dosage instructions, plus the number of tab-
lets or capsules prescribed. The duration in days for each
prescription was calculated by dividing the number of
tablets prescribed by the number to be taken per day in-
dicated by the dosage instructions. Where dosage direc-
tions were missing or unclear (just under 5 % of
prescriptions) we used the median duration from pre-
scriptions for the same drug where dosage was recorded,
accounting for the number of tablets prescribed, as in
our previous study [4, 9]. The total daily dose was gener-
ated by multiplying the dose per tablet by the number of
tablets to be taken each day. In order to make direct
comparisons between different antidepressant classes we
converted the total daily dose to a defined daily dose
(DDD) using the assumed average daily maintenance
dose as given for each antidepressant on the WHO web-
site (www.whocc.no/atc_ddd_index/). Where prescrip-
tions for the same drug were issued on the same day we
counted them as a single prescription and summed the
doses.
We classified antidepressant drugs according to the
classes in the British National Formulary (BNF) which
gives four main categories: tricyclic and related antide-
pressants (TCAs - section 4.3.1), selective serotonin re-
uptake inhibitors (SSRIs - section 4.3.3), monoamine
oxidase inhibitors (MAOIs - section 4.3.2), and other an-
tidepressants (section 4.3.4). We defined an additional
fifth category as combined prescriptions, comprising
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prescriptions for different drugs, either within a class or
from different classes, given on the same date; these pre-
scriptions were not included in analyses of dose.
In a similar way to the previous study [4, 9] the 11
most frequently prescribed individual antidepressants
were identified.
Confounding variables
Both demographic and baseline characteristics and co-
morbidities were included as confounding factors in the
adjusted analyses. These were a general pool of con-
founders considered likely to be associated with either
the selection of an antidepressant or the risk of the out-
come as in the previous study [9].
The demographic features were: age at study entry,
gender, year of index diagnosis of depression, severity of
index diagnosis of depression (categorised as mild, mod-
erate or severe, using the Read code classification pub-
lished by Martinez and colleagues [11] and some
additional classification by a member of the study team
(RM) of further Read codes for depression, present in
our data but not included in the Martinez study, see
Additional file 1: Table S2), Townsend deprivation score
(in fifths) [12], smoking status (non-smoker, ex-smoker,
current smoker coded as light (1–9 cigarettes/day), mod-
erate (10–19 cigarettes/day) or heavy (≥20 cigarettes/
day)), alcohol intake (none, trivial (less than 1 unit per
day), light (1 to 2 units per day), medium (3 to 6 units
per day), heavy (7 to 9 units per day) and very heavy
(more than 9 units per day)), and ethnicity categorised
as either white/not recorded or non-white (comprising
Indian, Pakistani, Bangladeshi, other Asian, black African,
black Caribbean, Chinese and other/mixed groups).
We also adjusted for 13 baseline comorbidities and for
usage of 11 drugs at baseline, including anticonvulsants.
A full list of these can be found in Table 1.
Statistical analysis
We used Cox’s proportional hazards models to analyse
the time to the first recorded diagnosis of epilepsy/sei-
zures and to assess any differences in risk associated
with the antidepressant prescribed. These analyses used
robust standard errors to account for clustering of pa-
tients within general practices. Patients with a previous
history of epilepsy/seizures were dropped from the co-
hort before proceeding with these analyses. Our analysis
treated antidepressant use as a time-varying exposure
which partitioned follow-up time for each patient into
treatment periods by antidepressant class and also any
periods of non-treatment between prescriptions. We
regarded a patient as not exposed to treatment during
periods where there was a gap of 90 days or more be-
tween the end of one prescription and the start of the
next. We based our main results on the first 5 years of
Table 1 Characteristics of the study cohort (N = 238,963) at
baseline
Characteristic n %
Gender
Male 92,935 38.89
Female 146,028 61.11
Age (years)
20-29 51,212 21.43
30-39 77,141 32.28
40-49 59,260 24.80
50-59 39,573 16.56
60-64 11,777 4.93
Mean age (SD)
Overall 39.54 (11.14)
Male 40.98 (11.13)
Female 38.61 (11.04)
Ethnicity
White/not recorded 227,451 95.18
Indian 1922 0.80
Pakistani 1714 0.72
Bangladeshi 1000 0.42
Other Asian 991 0.41
Caribbean 1520 0.64
Black African 1386 0.58
Chinese 307 0.13
Other/mixed 2672 1.12
Depression severity (index diagnosis)
Mild 171,208 71.65
Moderate 59,140 24.75
Severe 8615 3.61
Perinatal depressiona 18,259 12.50
Smokingb
Recorded 233,290 97.63
Non smoker 110,849 47.52
Ex smoker 35,132 15.06
Current smoker 87,309 37.43
Light smoker (1–9 per day) 24,104 10.33
Moderate smoker (10–19 per day) 40,546 17.38
Heavy smoker (≥20 per day) 22,659 9.71
Alcohol consumptionb
Recorded 203,189 85.03
Non drinker 55,253 27.19
Trivial (less than 1 unit per day) 77,579 38.18
Light (1–2 units per day) 51,310 25.25
Moderate (3 to 6 units per day) 14,482 7.13
Heavy (7 to 9 units per day) 2174 1.07
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follow-up after study entry, and also conducted analyses
for the first year of follow-up and for the whole of
follow-up time. We calculated unadjusted and adjusted
hazard ratios with 95 % confidence intervals, adjusting
for the confounding variables listed above.
The analysis of antidepressant treatment was con-
ducted in five main ways: by drug class (with no current
treatment as the reference group), drug class (with SSRIs
as the reference group), dosage, the 11 most common
antidepressants, and by time since starting and stopping
antidepressant treatment. Table 3 shows the categories
used. For the dosage analysis we did not calculate DDDs
for combined prescriptions, so only used one category
for them. For the time since starting and stopping ana-
lysis, periods of non-treatment from 183 days after stop-
ping treatment were coded as no use of antidepressants.
We tested for interactions between antidepressant
drug class and age, sex and ethnicity.
We determined statistical significance using a two-
tailed P value of <0.01, and used Wald’s significance
tests to assess differences between drug classes. We used
log-log plots and tests of the proportional hazards as-
sumption via Schoenfeld residuals, to check the validity
of our models.
Numbers needed to harm (NNH) and absolute risks
were calculated over 1 and 5 years based on the method
described for numbers needed to treat (NNT) by Altman
et al. [13, 14] using adjusted hazard ratios. The NNH for
a particular drug gives the number of patients that
would need to be treated with that drug, over a certain
period of time, for there to be one extra case of epi-
lepsy/seizures more than that occurring in the untreated,
comparison group. The quantity is generated by first cal-
culating the absolute risk increase by subtracting the
event rate in the treated group from that in the un-
treated control group (at a specific time), and then tak-
ing the reciprocal of that number. The NNH assumes a
causal relationship between each drug and the risk of
epilepsy/seizures.
All analyses were conducted with Stata/MP v12.1.
Sensitivity analyses
We performed two sensitivity analyses. In the first we
repeated the main analyses, but excluded patients who
received no antidepressant treatment during follow-up.
The reason for this analysis was to examine whether any
differences between the untreated and treated patients
that we were not able to account for in the analysis, such
as a preference for psychotherapy rather than drug treat-
ment, could introduce a form of selection bias into our
results.
In the second we repeated the analyses excluding pa-
tients on anticonvulsants at baseline, in case these had a
previous history of epilepsy that was unrecorded and
could bias the results, although anticonvulsant use is not
necessarily an indication of epilepsy or seizures as these
drugs are sometimes used in the treatment of other con-
ditions such as neuropathic pain [15].
Approvals
The project has been independently peer reviewed and
accepted by the QResearch Scientific board and has been
Table 1 Characteristics of the study cohort (N = 238,963) at
baseline (Continued)
Very heavy (over 9 units per day) 2391 1.18
Townsend deprivation quintileb
Recorded 230,762 96.57
1 (Least deprived) 45,021 19.51
2 46,207 20.02
3 48,293 20.93
4 47,063 20.39
5 (Most deprived) 44,178 19.14
Comorbidities
CHD 4109 1.72
Diabetes 7371 3.08
Hypertension 17,217 7.20
Stroke/TIA 1741 0.73
Cancer 3810 1.59
Epilepsy/seizures 3325 1.39
Hypothyroidism 5267 2.20
Obsessive-compulsive disorder 494 0.21
Rheumatoid arthritis 1301 0.54
Osteoarthritis 7228 3.02
Osteoporosis 867 0.36
Liver disease 698 0.29
Renal disease 549 0.23
Asthma/chronic obstructive airways disease 31,816 13.31
Medications at baseline
Anticonvulsants 2672 1.12
Antihypertensives 25,344 10.61
Anti-psychotics 836 0.36
Aspirin 7159 3.00
Anticoagulants 1073 0.45
Bisphosphonates 854 0.36
Hypnotics/anxiolytics 11,354 4.75
NSAIDs 12,725 5.33
Statins 10,823 4.53
Oral contraceptivesa 27,396 18.76
HRTa 7207 4.94
a Given percentage is for female patients only
b Percentages are out of the number recorded
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approved in accordance with the agreed procedure with
the Trent Research Ethics Committee (reference No
MREC/03/4/021).
Results
Our initial cohort consisted of 327,235 patients aged 20
to 64 years with a first diagnosis of depression recorded
between 1st January 2000 and 31st July 2011, and ex-
cluded temporary residents and those with a previously
recorded diagnosis of depression. We excluded a further
88,272 (27.0 %) patients. Of these, 7152 (2.2 %) patients
were excluded who had a diagnosis of schizophrenia, bi-
polar disorder or another psychosis. Also 83,824
(25.6 %) patients were excluded who either were pre-
scribed antidepressant medication more than 36 months
before the recorded date of depression diagnosis, before
their study entry date, or before the age of 20. These cri-
teria were not mutually exclusive and there was some
overlap between them. The number of patients in the
study cohort became 238,963 (73 % of the initial
sample).
Demographic characteristics of the cohort
Table 1 shows the baseline characteristics of the cohort.
There were 146,028 (61.1 %) females and 92,935
(38.9 %) males. The mean age was 39.5 years (SD = 11.1).
The most common comorbidity at baseline was
asthma and/or chronic obstructive airways disease
(31,816 patients, 13.3 %), followed by hypertension
(17,217 patients, 7.2 %). The most common medication
at baseline was antihypertensives (25,344 patients,
10.6 %). There were 2672 (1.1 %) patients on anticonvul-
sants at baseline.
Antidepressant treatment during follow-up
A total of 209,476 (87.6 %) patients received antidepres-
sant treatment during follow-up, with 3,337,336 anti-
depressant prescriptions issued during the whole of
follow-up. This mainly comprised SSRI prescriptions
(2,379,668, 71.3 %), with 533,798 (16.0 %) prescriptions
for TCAs, 422,079 (12.7 %) for other types of antidepres-
sant and only 1791 (<0.1 %) prescriptions for MAOIs.
The median duration of treatment during follow-up was
221 days (interquartile range 79 to 590 days), with 5.5 %
of patients having a total duration of treatment of 5 or
more years. Within the whole study period there were
over 1.3 million person-years of follow-up.
There were 168,457 prescriptions for two or more dif-
ferent antidepressants issued on the same date. After
counting these as single combined prescriptions the total
number of prescriptions became 3,252,633. Table 2 gives
information on the most frequently prescribed individual
antidepressants. The most frequently prescribed
Table 2 Number of prescriptions, DDD and doses prescribed for the 11 most commonly prescribed antidepressant drugs
Dose prescribed (mg/day)c
Antidepressant drug na %b DDD Mode Median IQR Min Max
Tricyclic and related antidepressants (TCA)
Amitriptyline hydrochloride 236,416 7.27 75 25 25 15 to 50 2.0 350.0
Dosulepin hydrochloride 125,302 3.85 150 75 75 50 to 150 12.5 325.0
Lofepramine 47,414 1.46 105 140 140 140 to 210 35.0 350.0
Trazodone hydrochloride 30,912 0.95 300 150 125 75 to 150 20.0 750.0
Selective serotonin reuptake inhibitors (SSRI)
Citalopram hydrobromide 1,023,255 31.46 20 20 20 20 to 20 2.5 120.0
Escitalopram 139,190 4.28 10 10 10 10 to 20 2.5 80.0
Fluoxetine hydrochloride 778,285 23.93 20 20 20 20 to 20 4.0 120.0
Paroxetine hydrochloride 159,389 4.90 20 20 20 20 to 30 4.0 100.0
Sertraline hydrochloride 213,749 6.57 50 50 50 50 to 100 12.5 400.0
Other antidepressants
Mirtazapine 142,400 4.38 30 30 30 15 to 45 3.8 112.5
Venlafaxine hydrochloride 205,984 6.33 100 75 112.5 75 to 150 9.4 600.0
All other antidepressants 66,553 2.05
Combined antidepressants 83,784 2.58
DDD defined daily dose
aNumbers of prescriptions where prescriptions for the same drug issued on the same day count as a single prescription and the doses have been summed
bPercentage out of total number of prescriptions = 3,252,633
c4.98 % of prescriptions had missing information on dosage
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antidepressant was citalopram with 1,023,255 (31.5 %)
prescriptions, followed by fluoxetine with 778,285
(23.9 %) prescriptions.
See Additional file 1: Table S3 for a breakdown of base-
line characteristics for the cohort by the type of antidepres-
sant first prescribed, including a column for those patients
not treated with antidepressants during follow-up.
Number of cases of epilepsy/seizures at baseline and
during follow-up
At baseline 3325 patients (1.4 %) had a previous diagno-
sis of epilepsy and/or seizures. We excluded these pa-
tients and also, due to small numbers, those with MAOI
prescriptions (n = 156) from further analyses leaving
235,489 patients (72 % of the initial sample).
During the entire follow-up period 1126 patients had a
first diagnosis of epilepsy/seizures. Within the first
5 years of follow-up 878 patients (416 women and 462
men) had a first diagnosis of epilepsy/seizures, giving an
incidence rate of 99 per 100,000 person-years (76 in
women and 135 in men).
Associations with epilepsy/ seizures over 5 years of
follow-up
Table 3 shows unadjusted and adjusted hazard ratios for
the first 5 years of follow up. All hazard ratios for the
different antidepressant drug classes were statistically
significant compared with periods of no use, with the
highest being for combined antidepressants (adjusted
HR 2.73, 95 % CI 1.52 to 4.91). There was no significant
difference between the drug classes overall (p = 0.254).
All dose categories other than low doses of SSRIs and
other antidepressants were associated with a significantly
increased risk (at P < 0.01) of epilepsy/seizures compared
to periods of no treatment. Hazard ratios increased with
dose for SSRIs but for TCAs and other antidepressants
the middle dose categories had the highest hazard ratios.
There were significantly increased hazard ratios for 8
of the 11 most commonly prescribed drugs with the
highest risks associated with trazodone (adjusted HR =
5.41, 95 % CI 3.05 to 9.61), lofepramine (adjusted HR =
3.09, 95 % CI 1.73 to 5.50), and venlafaxine (adjusted
HR = 2.84, 95 % CI 1.97 to 4.08). Escitalopram, sertraline
and mirtazapine, were not associated with a significant
increase in risk (at P < 0.01). Wald’s tests however did
not indicate any significant difference overall between all
the individual antidepressant drugs (P = 0.029).
When compared against the drug citalopram, only
trazodone (HR = 2.66, 95 % CI 1.49 to 4.76) had a sig-
nificantly increased risk of epilepsy/seizures. Full results
of analyses of direct comparisons with mid-dose SSRIs
and citalopram are shown in Additional file 1: Table S4.
In the analysis of duration (Table 3 and Fig. 1), there
were no clear patterns of risk and all hazard ratios were
significant except for SSRIs in the first 28 days of treat-
ment and other antidepressants in the 29–84 days cat-
egory. In the time since stopping treatment categories
only 3 were statistically significant: the first 28 day
period for SSRIs (adjusted HR 2.28, 95 % CI 1.50 to
4.36) and the 29–84 day periods for TCAs (adjusted HR
2.79, 95 % CI 1.65 to 4.72), and other antidepressants
(adjusted HR 4.46, 95 % CI 2.46 to 8.09). However num-
bers were small in some categories.
Interaction models
There were no statistically significant interactions be-
tween drug class and either age, sex or ethnicity.
Sensitivity analyses
In the first sensitivity analysis excluding untreated pa-
tients, although all hazard ratios increased slightly, only
one result, for low dose SSRI, went from borderline sig-
nificance to statistical significance (HR from 1.80 to
1.88, with P moving from 0.011 to 0.006) (Additional file
1: Table S5).
In the second sensitivity analysis omitting patients on
anticonvulsants at baseline (Additional file 1: Table S6),
most hazard ratios increased with the significance levels
largely remaining unchanged. For individual drugs the
only hazard ratio to decrease was for escitalopram, going
from 1.49 to 1.33. The greatest increase was for trazo-
done (HR from 5.41 to 5.95).
Associations with epilepsy/seizures over 1 year’s follow-up
We repeated the analyses restricted to the first year of
follow-up and the hazard ratios tended to be lower and
with wider confidence intervals due to the reduced num-
ber of events (Additional file 1: Tables S7 and S8).
Absolute risks of epilepsy/seizures
Numbers needed to harm (NNH) and absolute risks over
one and five years of follow-up are shown in Table 4.
These assume a causal association, and confidence inter-
vals are only shown for the drugs with statistically sig-
nificant associations with epilepsy/seizure risk based on
the adjusted hazard ratios.
The drug class with the highest NNH is the SSRIs:
2014 patients would have to be treated for a year for
there to be one extra case of epilepsy/seizures. Over five
years 312 patients would have to be treated for an extra
case. At the other end of the spectrum, only 166 patients
would have to be treated with a combined prescription
for five years, for there to be an extra case. For individ-
ual drugs the lowest NNH is for trazodone, where for
one extra case of epilepsy/seizures to occur 602 patients
would have to be treated for one year, and only 65 pa-
tients would have to be treated for five years. Although
the NNH over one year for lofepramine and venlafaxine
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Table 3 Unadjusted and adjusted 5-year hazard ratios for epilepsy/seizures by antidepressant class, dose, duration and individual
drug
No. of
eventsa
Person
yearsb
Unadjusted analyses Adjustedc analyses
HR 95 % CI P HR 95 % CI P
Antidepressant class
No current use 384 566,890 1.00 1.00
TCAs 82 41,130 2.83 2.22 3.62 <0.001 2.32 1.79 3.01 <0.001
SSRIs 309 224,600 1.97 1.69 2.31 <0.001 1.92 1.63 2.25 <0.001
Other antidepressants 58 27,820 3.11 2.39 4.05 <0.001 2.33 1.76 3.10 <0.001
Combined antidepressants 13 4220 4.70 2.77 7.98 <0.001 2.73 1.52 4.91 0.001
Antidepressant class and dose categoriesd
No current use 384 566,890 1.00 1.00
TCA: ≤ 0.5 DDD 38 23,520 2.26 1.59 3.21 <0.001 1.91 1.32 2.76 0.001
TCA: >0.5 DDD/≤ 1.0 DDD 28 8370 4.85 3.31 7.11 <0.001 3.65 2.46 5.42 <0.001
TCA: > 1.0 DDD 14 5240 3.69 2.18 6.24 <0.001 2.94 1.72 5.03 <0.001
SSRI: ≤ 0.5 DDD 19 15,970 1.67 1.06 2.61 0.027 1.80 1.15 2.84 0.011
SSRI: >0.5 DDD/≤ 1.0 DDD 213 157,490 1.92 1.60 2.30 <0.001 1.90 1.57 2.29 <0.001
SSRI: > 1.0 DDD 67 42,410 2.31 1.80 2.97 <0.001 2.03 1.56 2.64 <0.001
Other: ≤ 0.5 DDD 6 4000 2.09 0.95 4.61 0.068 1.71 0.77 3.82 0.187
Other: >0.5 DDD/≤ 1.0 DDD 31 13,090 3.71 2.64 5.20 <0.001 2.66 1.85 3.83 <0.001
Other: > 1.0 DDD 19 8330 3.21 2.01 5.13 <0.001 2.54 1.56 4.11 <0.001
Combined antidepressants 13 4220 4.70 2.77 7.97 <0.001 2.73 1.52 4.91 0.001
Antidepressant class by duration
No current usee 333 508,970 1.00 1.00
TCA first 28 days 12 5470 2.85 1.52 5.36 0.001 2.40 1.28 4.47 0.006
TCA 29 to 84 days 16 5380 4.65 2.86 7.59 <0.001 3.76 2.29 6.18 <0.001
TCA 85 or more days 36 18,900 2.86 2.02 4.05 <0.001 2.16 1.49 3.14 <0.001
SSRI first 28 days 27 20,590 1.67 0.94 2.95 0.079 1.61 0.92 2.83 0.098
SSRI 29 to 84 days 36 27,800 2.14 1.46 3.12 <0.001 2.03 1.39 2.97 <0.001
SSRI 85 or more days 185 127,070 2.17 1.81 2.61 <0.001 2.07 1.70 2.51 <0.001
Other first 28 days 10 2750 4.96 2.58 9.53 <0.001 3.93 2.04 7.56 <0.001
Other 29 to 84 days 3 3480 1.71 0.64 4.57 0.283 1.02 0.33 3.21 0.968
Other 85 or more days 30 16,740 2.78 1.96 3.95 <0.001 2.03 1.41 2.94 <0.001
Combined, all time 13 3850 5.35 3.15 9.09 <0.001 2.99 1.65 5.40 <0.001
TCA 1–28 days after stopping 3 3610 1.28 0.41 3.95 0.668 1.14 0.37 3.54 0.818
TCA 29–84 days after stopping 15 7020 3.12 1.86 5.24 <0.001 2.79 1.65 4.72 <0.001
TCA 85–182 days after stopping 8 10,690 1.30 0.69 2.45 0.425 0.95 0.47 1.92 0.880
SSRI 1–28 days after stopping 23 15,640 2.24 1.47 3.39 <0.001 2.28 1.50 3.46 <0.001
SSRI 29–84 days after stopping 33 30,320 1.66 1.14 2.44 0.009 1.60 1.07 2.37 0.021
SSRI 85–182 days after stopping 41 46,690 1.31 0.94 1.81 0.109 1.25 0.89 1.76 0.197
Other 1–28 days after stopping 3 1560 2.86 0.93 8.79 0.067 2.39 0.77 7.39 0.131
Other 29–84 days after stopping 11 2990 5.79 3.27 10.28 <0.001 4.46 2.46 8.09 <0.001
Other 85–182 days after stopping 8 4490 2.52 1.25 5.08 0.010 2.17 1.08 4.36 0.030
Combined 1–182 days after stoppingf 0 660 n/a - - - n/a - - -
Antidepressant drug
No current use 384 566,890 1.00 1.00
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are higher at 2565 and 749 respectively, they are only
138 and 156 for five years of follow-up. Of all the indi-
vidual antidepressants, these three drugs have the lowest
NNH over five years of follow-up, with trazodone having
almost twice the absolute risk as the other two.
Discussion
We have conducted a large study of primary care pa-
tients aged 20–64 years with depression and with no
previous diagnosis of epilepsy/seizures. We have
assessed and quantified the absolute risk of epilepsy
Table 3 Unadjusted and adjusted 5-year hazard ratios for epilepsy/seizures by antidepressant class, dose, duration and individual
drug (Continued)
Amitriptyline (TCA) 34 19,550 2.46 1.75 3.46 <0.001 1.94 1.35 2.78 <0.001
Dosulepin (TCA) 21 12,120 2.55 1.63 3.97 <0.001 2.19 1.38 3.47 0.001
Lofepramine (TCA) 12 4750 3.48 1.97 6.14 <0.001 3.09 1.73 5.50 <0.001
Trazodone (TCA) 12 2320 7.20 4.08 12.71 <0.001 5.41 3.05 9.61 <0.001
Citalopram (SSRI) 136 93,940 2.07 1.71 2.52 <0.001 2.03 1.66 2.49 <0.001
Escitalopram (SSRI) 14 13,310 1.47 0.83 2.58 0.185 1.49 0.84 2.63 0.171
Fluoxetine (SSRI) 111 81,780 1.94 1.55 2.42 <0.001 1.92 1.52 2.41 <0.001
Paroxetine (SSRI) 26 16,500 2.35 1.50 3.67 <0.001 2.02 1.27 3.23 0.003
Sertraline (SSRI) 22 18,790 1.71 1.12 2.61 0.013 1.56 1.01 2.42 0.045
Mirtazapine (other) 17 10,070 2.35 1.47 3.78 <0.001 1.72 1.06 2.80 0.028
Venlafaxine (other) 36 15,500 3.61 2.59 5.02 <0.001 2.84 1.97 4.08 <0.001
All other antidepressants 8 4910 2.30 1.16 4.54 0.017 1.67 0.84 3.33 0.143
Combined antidepressants 13 4220 4.70 2.77 7.98 <0.001 2.71 1.50 4.87 0.001
DDD defined daily dose
aBased on numbers in adjusted analysis. For the first 5 years of follow-up there were 878 cases of epilepsy/seizures in total, and 1126 in total for the whole of
follow-up. The total number of cases here is less than 878 due to some being dropped due to missing data on covariates
bPerson years of exposure, based on adjusted analyses
cAdjusted for age, sex, year of diagnosis of depression, severity of depression, deprivation, smoking status, alcohol intake, ethnic group (white/not recorded or
non-white), coronary heart disease, diabetes, hypertension, cancer, hypothyroidism, osteoarthritis, asthma/chronic obstructive airways disease, stroke/TIA, rheumatoid
arthritis, osteoporosis, liver disease, renal disease, obsessive-compulsive disorder, statins, NSAIDS, aspirin, antihypertensive drugs, anticonvulsants, hypnotics/anxiolytics,
oral contraceptives, hormone replacement therapy, antipsychotics, bisphosphonates, anticoagulants
dTotal numbers in the analysis of dosage are less due to missing data on dose
eNumber of events in the no treatment group is less due to some now being included in the time since stopping categories
fThere were no events in the 1–182 days after stopping for combined antidepressants
Fig. 1 Adjusted hazard ratios and 95 % confidence intervals for epilepsy/seizures, for time since starting and stopping treatment by drug class
over 5 years of follow-up. Note: numbers above each arrow are the number of cases of epilepsy/seizures in that category
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associated for different classes and individual types of
antidepressant. Our analyses have found that all classes
of antidepressant were associated with a statistically sig-
nificant increase in epilepsy/seizures when compared
with periods of no treatment. These associations
remained for all dose levels for TCAs and for all doses
(other than low doses) of SSRIs and other types of anti-
depressant. There was also an increased risk of epilepsy/
seizures in patients prescribed combined antidepressant
treatment, but there were relatively few cases in this
group, so the result should be treated with caution.
Of the 11 individual drugs we examined, all except ser-
traline, escitalopram and mirtazapine were significantly
associated with the risk of epilepsy/seizures. Individual
drugs with the highest risks were trazodone, lofepramine
and venlafaxine. When compared against citalopram, the
most commonly prescribed antidepressant, only trazo-
done had a significantly increased risk of epilepsy/sei-
zures. Regarding duration of treatment, there were no
clear patterns of risk although for all drug classes the
risk of epilepsy/seizures remained significantly increased
more than 12 weeks after starting treatment.
The statistically significant increases in risk of epi-
lepsy/seizures described above, for all drug classes and
for most dose categories and individual drugs remained
largely unchanged when we omitted patients not receiv-
ing any antidepressant treatment during follow-up.
When we excluded those taking anticonvulsants at base-
line the hazard ratios tended to increase. This result
confirms the expectation that anticonvulsants increase
the fit threshold, and therefore may reduce the risk of
epilepsy/seizures associated with antidepressant use. In
effect, by including patients on anticonvulsants at base-
line in the cohort, the hazard ratios for antidepressant
use are attenuated.
Although all the drug classes and most individual
drugs were associated with an increased risk of epilepsy/
seizures, the NNH over the first year are quite high and
mainly in the thousands, with absolute risks mostly less
than 2 in 1000. Only combined prescriptions and the
drugs trazodone and venlafaxine have NNH values
below one thousand for the first year of treatment.
Therefore in the main, for courses of antidepressant
treatment that are less than one year, the absolute risk is
present but low.
It is only under long term treatment, as in our ex-
ample of five years that the NNH drop into the several
hundred. Here, the absolute risks range from 7 per 1000
Table 4 Numbers needed to harm (NNH) for epilepsy/seizures, at 1-year and 5-years of follow-up for drug class and individual
antidepressant
1 year follow-up 5 years follow-up
Absolute risk per 1000a NNH 95 % CIb Absolute risk per 1000a NNH 95 % CIb
TCA 1.6 1437 609 to 9786 8.1 217 143 to 363
SSRI 1.4 2014 1014 to 7458 6.7 312 229 to 453
Other 1.8 1125 472 to 6274 8.2 215 137 to 378
Combined 5.5 217 82 to 705 9.5 166 74 to 551
Tricyclic and related antidepressants (TCA)
Amitriptyline 1.7 1332 - 6.8 306 161 to 819
Dosulepin 1.5 1572 - 7.6 241 117 to 748
Lofepramine 1.3 2565 - 10.8 138 64 to 392
Trazodone 2.6 602 - 18.8 65 34 to 140
Selective serotonin reuptake inhibitors (SSRI)
Citalopram 1.8 1126 614 to 2745 7.1 278 193 to 434
Escitalopram 1.2 3003 - 5.2 586 -
Fluoxetine 1.3 2697 - 6.7 313 204 to 546
Paroxetine 1.0 18372 - 7.1 280 129 to 1072
Sertraline 0.7 −4684 - 5.5 508 -
Other antidepressants
Mirtazapine 1.2 2962 - 6.0 396 -
Venlafaxine 2.2 749 296 to 3731 9.9 156 93 to 294
All others 1.3 2383 - 5.8 426 -
Combined 5.5 216 82 to 700 9.4 168 74 to 569
aAbsolute risk of epilepsy/seizures in the no treatment group is 0.9 and 3.5 after 1 year and 5 years of follow-up respectively
bConfidence intervals are not shown where the HR is not statistically significant
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(SSRIs) to 10 per 1000 (combined) for the drug classes.
For individual antidepressants, the drugs with the high-
est absolute risks over 5 years are: venlafaxine (10 per
1000), lofepramine (11 per 1000) and trazodone (19 per
1000). Therefore our results show that those patients re-
ceiving treatment courses in line with guidelines (around
180 days) will have a low absolute risk of epilepsy/sei-
zures. However patients on longer courses will accumu-
late a moderate absolute risk, which can vary and be
quite high depending on the specific drug.
Comparison with other studies
Whilst the association between epilepsy/seizures and de-
pression [8, 16, 17] and that between antidepressant use
and epilepsy/seizures [18] has been previously docu-
mented, some of this evidence is conflicting. For ex-
ample some studies claim the effects of antidepressants
are anticonvulsant rather than pro-convulsant [19] and
other studies claim that most if not all antidepressants
lower the seizure threshold [3].
There are studies concerned only with a population
already predisposed to the outcome [20–24], however
their results may not be directly comparable to ours as
we omitted patients with a history of epilepsy/seizures.
One of these studies [20] concluded that patients could
be safely treated with antidepressants from the TCA or
SSRI groups without any significant increase in seizure
frequency. However the study only looked at the first
12 months of treatment, only included two of the anti-
depressants that we did (amitriptyline and paroxetine)
and was much smaller than our study (n = 421).
Another large study utilising drug safety data [24] con-
cluded that SSRIs and the antidepressants mirtazapine,
venlafaxine and duloxetine might be more appropriate
for treating depression than TCAs, in patients with an
enhanced seizure risk. They based their analysis on
counting the number of grand mal seizures in patients
undergoing antidepressant treatment in psychiatric in-
patient settings. A limitation of this analysis is that sei-
zures were probably underreported.
A further issue is whether the antidepressants are
given in low doses, normal therapeutic doses, or taken
in overdose. For example, there is evidence that citalo-
pram has the ability to induce seizures if taken in over-
dose [25] and that it is more toxic and more likely to
provoke seizures in overdose than escitalopram [26].
However a review by Nemeroff [27] concluded that
doses of between 20–60 mg of citalopram do not in-
crease risk of seizure.
A study utilising Food and Drug Administration
(FDA) Summary Basis of Approval (SBA) Reports in the
United States [28] concluded that many second-
generation antidepressants, several of which are included
in our study (including citalopram and venlafaxine), have
anticonvulsant properties. They based their conclusions
on comparing seizure incidence between treatment and
placebo arms of clinical trials, with numbers of partici-
pants less than 5000 in most instances, and with short
follow-up periods (the mean duration of the treatment
arms was only 116 days, with the mean duration of the
placebo arms only 78 days). They also found an inci-
dence of seizures in the placebo groups approximately
19 times that seen in the general population.
These results may seem to contradict our own, but
many of the placebo arms of the studies included in the
Alper [28] paper did not report the number of seizures,
a limitation which they acknowledge. In addition, al-
though many of the antidepressants they looked at are
also included in our study, they did not treat each anti-
depressant individually, but rather they combined them
together and compared the overall seizure rate with the
placebo arms. Also, seizures are only recorded in SBA
reports if the FDA staff physician deems the event was
unlikely to have been provoked by an external factor,
such as alcohol withdrawal, and could be safely attrib-
uted to the drug in question. Our study included all
events, without an attempt to distinguish between the
possible causes. Generally clinical trials are designed to
answer questions regarding benefits of treatments rather
than safety and full reporting of adverse effects is often
unavailable [29].
In an analysis [30] of the WHO adverse drug reactions
(ADR) database, the authors concluded that antidepres-
sant treatment, lowers the seizure threshold and pro-
vokes seizures. They looked at 9 of the 11 most
commonly prescribed antidepressant medications that
we did. There were some differences in their results
compared to ours though, since they showed trazodone
to have one of the lowest ratios of suspected seizures.
There were many limitations to their study however, in-
cluding the fact that the total number of patients treated
with a particular drug was unknown making direct com-
parisons with our results inappropriate.
In our previous study in people aged 65 years and over
[4, 9] we found that SSRIs and other antidepressants
were associated with an increased risk of epilepsy/sei-
zures. This situation has been repeated in the present
study, with adjusted hazard ratios very similar to the
earlier study. Also, citalopram, paroxetine, and venlafax-
ine were found to be significantly associated with an in-
creased risk of epilepsy/seizures in both studies.
The significant association with sertraline in the earlier
study is no longer present whereas there is now a signifi-
cant association with fluoxetine. But the main difference
is that in the present study we have found a significant
association with TCAs when before there was none.
The previous study reported an adjusted hazard ratio
of 1.02 for TCAs for older people but for the present
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study it was 2.32. In the previous study, none of the four
TCAs were significantly associated with epilepsy/seizure
risk, however in the present study they are all associated
with a statistically significant increased risk with the
highest hazard ratio being for trazodone.
Why TCAs should be significantly associated with an
increased risk of epilepsy/seizures in the younger sample
but not the older sample is unclear, particularly since the
proportion of TCA prescriptions in the present study is
far less than the earlier study: 31.6 % vs. 13.3 %. Al-
though there were fewer low dose TCA prescriptions in
the new study compared to the older study (60 % vs.
70 % were for ≤ 0.5 DDD), this is not enough to explain
the difference between the two results.
Strengths and limitations
We know of no other study utilising a sample as large,
and followed-up for as many years as our cohort. We
were able to analyse a range of antidepressant medica-
tions, including individual drugs and accounted for
many confounding factors. We also calculated absolute
risks that enable comparisons to be made between dif-
ferent drugs that can be explained to patients.
We have used a very large sample representative of
primary care populations where most treatment deci-
sions are made, so our results are likely to be
generalizable to people aged 20 to 64 years with a diag-
nosis of depression in primary care.
Our study included all eligible patients within the study
time period, and did not exclude people with any comor-
bid disease or taking any medications other than those ex-
plicitly stated in the exclusion criteria (patients with
diagnoses of schizophrenia, bipolar disorder or other types
of psychosis, and those prescribed lithium or anti-manic
drugs). This limited the potential for selection bias which
can affect observational studies. Recall bias was avoided as
data on prescriptions and confounding factors were re-
corded prospectively on the computer system.
We had access to detailed information on antidepres-
sant prescriptions, including class of antidepressant,
drug name, dosage and duration, so were able to investi-
gate associations with these factors.
To reduce the effects of bias we adjusted for many
confounding factors, however we were unable to control
for certain factors such as family history of seizures,
seizure history without diagnosis, neurological abnor-
malities, or other factors known to affect seizure thresh-
old such as antibiotic use [31–34] so there may be some
residual confounding. Although we adjusted for depres-
sion severity, this was based on a logical but crude clas-
sification of diagnostic Read codes that has not been
formally validated, since depression severity scores are
not routinely recorded in general practice.
We excluded patients with a history of epilepsy/sei-
zures at baseline thereby reducing the possibility of a
drug being prescribed on the basis of whether it was
known to affect the seizure threshold (channelling bias).
The generally similar patterns of risk for the different
drug classes and individual drugs might indicate that de-
pression itself rather than its treatment could be the
cause of the increased rates of epilepsy/seizures. We re-
stricted our cohort to patients who had a diagnosis of
depression to reduce this potential indication bias how-
ever we compared rates during periods of treatment,
with untreated periods when the depression may have
resolved. Several studies have reported that depression is
associated with increased rates of epilepsy/seizures in-
cluding a bidirectional relationship [8, 16, 17], although
it is difficult to fully separate the effects of depression
from those of antidepressant treatment.
We do not know whether patients took their medica-
tion at the exact prescribed dose or whether they com-
pleted the course of medication. As a result, this may
mean some periods of antidepressant treatment have
been misclassified.
Our outcome was a diagnosis of epilepsy/seizures as
recorded in the general practitioners record. The nature
of the database and the study design meant that this
could not be formally adjudicated as might be the case
in a clinical trial. However since epilepsy is considered a
major diagnosis with consequences which can affect a
person’s employment or ability to drive, we think it is
unlikely that it would be entered in the record without
there being sufficient evidence to support the diagnosis.
Also epilepsy has been a condition included in the GP
Quality and Outcomes framework over recent years and
this is likely to have resulted in increased diligence re-
garding the accuracy of the diagnosis recorded on the
computer system. Another limitation of our study is that
we were not able to distinguish between seizures that were
epileptic and non-epileptic in nature, such as psychogenic
non-epileptic seizures. There is no reason to believe how-
ever that different antidepressants would have a differen-
tial effect on inducing non-epileptic seizures.
Implications of our findings
Whilst we acknowledge our results need further con-
firmation via future studies, there are possible implica-
tions of our findings for the treatment of depression.
We have found that treatment with all antidepressants
is associated with an increased risk of epilepsy/seizures,
with some types of antidepressant being associated with
a much higher risk than others. This suggests there is a
need to inform patients and their doctors about the in-
creased risks of continued antidepressant therapy that
accumulate over long periods of treatment. Consider-
ation of each patient’s individual circumstances must be
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taken into account, allowing discussion between the
clinician and the patient, enabling a shared decision to
be reached on future treatments.
Due to the increased absolute risks of epilepsy/seizures
that occur under long term use, there is a need for an
individual clinical risk-benefit assessment for any patient
facing antidepressant treatment over a period of five or
more years, bearing in mind the absence of evidence
supporting longer term treatment with antidepressants.
This may be of particular importance to people with
mild and infrequently recurring depression, or those
with additional risk factors for seizures such as evidence
of cerebrovascular disease.
In instances of mild depression in particular there
may be a case for stopping treatment, or a reduced
daily dosage, or switching to a different antidepressant
that carries a lower risk or seeking alternative treat-
ments, such as cognitive behavioural therapy, rather
than continuing with long-term antidepressant treat-
ment which would carry a further increased risk of
epilepsy/seizures.
In instances where the choice of antidepressant and
dose has already been driven by factors such as how well
the patient tolerates the drug or the severity of the de-
pression, our findings can still inform the continued
treatment of the patient as the accumulating risk that
occurs over time that we have demonstrated can be
communicated to the patient by the clinician. An in-
formed decision can then be reached regarding contin-
ued antidepressant treatment or alternative options from
that point forwards.
Conclusions
The increased risk to patients of epilepsy/seizures during
antidepressant treatment needs to be weighed against
the potential benefits of treatment, and whether the pa-
tient is on short term treatment which may not carry a
clinically important increased risk or on longer term
treatment where there is an accumulating risk over time.
Consideration of each patient’s individual circumstances,
and the choice of antidepressant, duration and dose,
may play a part in deciding whether any increased risks
of epilepsy/seizures are acceptable.
More research is needed to further clarify the situ-
ation with respect to the association between anti-
depressant use and the risk of epilepsy/seizures,
taking account of the type, severity and number of
seizures over time, whether patients have an existing
predisposition to epilepsy/seizures, and accounting for
other cofactors such as co-prescriptions, that may in-
fluence this relationship. Residual confounding and
indication bias may also influence our results, so they
need to be interpreted with caution.
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